Incyte Corporation

According to a recent report from Jefferies, Incyte (NASDAQ: INCY) has received positive feedback from physicians on ruxolitinib at EHA. After speaking to six physicians regarding their feedback on ruxolitinib, Jefferies remains confident in ruxolitinib's approval and a successful product launch...

According to a recent report, Piper Jaffray has initiated an Overweight rating and $23.00 price target on Incyte (NASDAQ: INCY). The company also expects ruxolitinib to grow beyond CYT387 launch; however, the current price target assumes no growth after the 2015-16 launch. In the report, Piper...

Piper Jaffray has initiated coverage on Incyte Corporation (NASDAQ: INCY) with an Overweight rating and $23 price target.

According to a recent report, Incyte (NASDAQ: INCY) presented at Jefferies 2011 Global Healthcare Conference and provided an positive update on potential ruxolitinib pricing. Additional topics discussed included the potential label on ruxolitinib, an update on the company's pricing strategy and...

Brean Murray Carret & Company has raised the price target on Incyte Corporation (NASDAQ: INCY) from $23 to $25 and maintains its Buy rating.

Goldman Sachs initiated coverage of Incyte Corporation (NASDAQ: INCY) with a Neutral rating and a price target of $20. In a research report published today, Goldman states, "We see INCY as a high-quality story that could potentially have the first- in-class drug ruxolitinib to treat myelofibrosis...

Goldman Sachs has initiated Incyte Corporation (NASDAQ: INCY) with a Neutral rating and $20 price target.

J.P. Morgan maintains an Overweight rating on Incyte Corporation (NASDAQ: INCY) and are increasing their Dec 2011 price target to $23 from $18.

In a report released this morning, J.P. Morgan said that it is attending the Annual Meeting of the American College of Rheumatology (ACR) in Atlanta where encouraging 6-mos Phase 2a data were presented this afternoon for Incyte Corporation (NASDAQ: INCY) and Eli Lilly's (NYSE: LLY) Jak inhibitor,...

Leerink Swann analysts Joshua Schimmer and Steve Y. Yoo reiterated their Outperform rating for shares of Incyte Corporation (Nasdaq: INCY) with a price target in "in the high-teens". They said that with an SPA from the FDA for the INCB18424 Phase III program, Incyte Corporation is well on its way...